Heiko Wurdak

• Reviewing the state of play of target identification and validation, and business rationale to explore newly discovered targets
• Leveraging human genetic data to understand the efficacy of new drugs
• Discussing the optimal moment for a biotech to partner a novel target identified through an innovative platform and whether the current deal-making landscape is favouring first-in-class or best-in-class

What is this session?

At the intersection of innovative research and business conversations, this forum facilitates the pitching of biotech pipelines and platforms to pharma and investors.

How does this session work?

As you register, secure one of the 15-minute presentation slots available in this presentation session. There will be no conflicting content happening to ensure a full and engaged audience listening to your presentation. We will add your talk to this brochure and on our website to showcase your differentiation in the best light, and host your company description and logo on the website as a company at the forefront of innovation.

1:30 – NIDB-3101: A Biparatopic Tau Antibody Binding Broadly & Neutralizing Tau Seeding Activity Using Alzheimer’S Disease Brains Presented by Discoveric bio alpha & gamma

1:45 – Neurodawn: A Commercial-Stage Biotech – CNS Portfolio, Multi-Asset Clinical Progress & Global Partnering Opportunities Presented by Neurodawn

2:00 – Presentation by KeifeRx

2:15 – Assemblify: Data-driven in bio Modelling for CNS therapeutics Presented by Assemblify